How a Milwaukee Lab is Shaping the Future of Drug Discovery
Protein Foundry was featured in MKE Startup News, highlighting our growing role in Milwaukee’s expanding biotech landscape. The article, titled Protein Foundry: Milwaukee’s Medical Foundry, offers a closer look at how we support global biomedical research by producing high quality recombinant chemokines and cytokines for both academic and industrial use.
The article emphasizes Protein Foundry's mission to bridge a critical gap in the drug discovery process. We do this by ensuring researchers have access to pure, bioactive proteins that mirror the natural structure and function found in the human body.
Dr. Brian Volkman, president of Protein Foundry, explains, “...we make sure that 100 percent of the final product has the correct three-dimensional structure. That is why customers get consistent results and come back for more.”
Our approach is shaped by the same discipline that defines successful academic research. From clear value propositions and thorough validation testing, Protein Foundry holds itself to a standard that satisfies both peer-reviewed science and commercial demands.
Volkman states, "You have to come up with an idea to sell to a customer, in this case the NIH, to get funding to pursue your research. The difference is that the product usually is not a commercial product. It is new knowledge, with occasional inventions.”
The article also points to Protein Foundry's long history of collaboration with institutions such as the Medical College of Wisconsin. Protein Foundry remains deeply rooted in research while continuing to grow its reach as a trusted provider of chemokines and cytokines.
Proudly based in Milwaukee, we are committed to translating academic expertise into real world scientific progress, one protein at a time.
Read the full article: Protein Foundry: Milwaukee’s Medical Foundry
